The Pharmacy Times® COVID-19 Resource Center is a comprehensive resource for clinical news and expert insights on COVID-19, an infectious disease caused by the SARS-CoV-2 virus, including vaccine information and treatments for the disease.
August 28th 2025
COVID-19 vaccination significantly reduces the risk of asthma and other airway inflammatory diseases, offering vital protection against respiratory complications.
August 27th 2025
The FDA's approvals follow new COVID-19 guidance announced by the commissioner of the agency in May 2025, focusing future approvals on older adults.
August 26th 2025
Rhinovirus infection, which causes the common cold, could offer infected children more respiratory pathway protection from SARS-CoV-2 infection.
August 20th 2025
The development of multisystem inflammatory syndrome in children infected with SARS-CoV-2 was associated with more marked shifts in metabolic parameters, leading to increased cardiovascular disease risk.
August 11th 2025
Individuals who have survived childhood cancer had a higher risk of developing a severe COVID-19 infection, while exhibiting a lower risk of contracting the virus.
Change Management Is a Consideration Beyond the Pandemic
Thoughtful application can reduce resistance and improve overall operations, if consistent steps are followed.
Read More
Study: Face Masks Strongly Associated With Reducing Health Care Workers' Risk of Acquiring COVID-19
March 31st 2021The team discovered a correlation between the implementation of Henry Ford’s universal mask policy and a significant drop in the rate at which its health care workers tested positive for SARS-CoV-2.
Read More
Study: Vitamin D Supplementation Could Protect From Severe COVID-19
March 31st 2021Earlier research has found that vitamin D supplementation can prevent inflammation in other respiratory diseases, but there have been limited studies examining the role of vitamin D supplementation in COVID-19.
Read More
Pfizer-BioNTech COVID-19 Vaccine Shows Positive Topline Results in Adolescents
March 31st 2021The results from a phase 3 trial in a population of American adolescents aged 12 to 15 years found that the Pfizer-BioNTech COVID-19 vaccine BNT162b2 showed 100% efficacy and robust antibody responses.
Read More
APhA Applauds Expansion of Activated Pharmacies in National COVID-19 Vaccination Strategy
March 30th 2021The Biden administration has moved to activate 40,000 local pharmacies within the Federal Retail Pharmacy Program, which is a part of the administration’s national COVID-19 vaccination strategy.
Read More
Frontline Health Care Workers Are Helping to Shape COVID-19 Vaccine Toolkit Resources
March 25th 2021Farah Towfic, PharmD, MBA, director, CEO operations at US Pharmacopeia (USP), discusses USP’s release of an updated version of its COVID-19 Vaccine Handling Toolkit in response to feedback from independent pharmacies to mass vaccination clinics.
Watch
Board Certification for Medical Science Liaisons: Implications for the Pharmaceutical Industry
March 24th 2021More than ever, confidence in objective, science-based data about therapeutics, such as the COVID-19 vaccine and other health care services, is a shared imperative across the pharmaceutical industry, health care communities, and the American public.
Read More
Fauci: DSMB Challenge of New AstraZeneca COVID-19 Vaccine Data Is an ‘Unfortunate Incident’
March 23rd 2021Following a review of the latest interim data released by AstraZeneca on its US phase 3 clinical trial assessing the 2-dose AZD1222 COVID-19 vaccine, the Data and Safety Monitoring Board (DSMB) expressed concern at the inclusion of what may have been outdated data.
Read More
Phase 3 Trial of Adjuvanted COVID-19 Vaccine Candidate Commences Enrollment in the US, Canada
March 23rd 2021Phase 3 clinical testing of a plant-derived COVID-19 vaccine candidate in combination with a pandemic adjuvant commenced following approval to proceed with participant enrollment from regulatory authorities in both Canada and the United States.
Read More
Review Confirms Nasal Hygiene Measures Are Effective to Protect Against COVID-19
March 23rd 2021Intranasal administration of virucidal and antiviral therapies may provide added clinical benefit by decreasing viral activity in the nasal pathway, preventing COVID-19 transmission and managing disease severity.
Read More
First Participants Dosed in Phase 2/3 Study on Moderna’s COVID-19 Vaccine in Pediatric Population
March 22nd 2021The first participants were dosed in the phase 2/3 KidCOVE study investigating vaccine candidate mRNA-1273 against COVID-19 in children aged 6 months to less than 12 years of age.
Read More
2 Commerce Drive
Cranbury, NJ 08512